NCT06912295View on ClinicalTrials.gov

Assess the Safety, Tolerability, and Pharmacokinetics of HL-1186 in Healthy Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

March 21, 2025

Primary Completion Date

August 30, 2025

Study Completion Date

October 9, 2025

Conditions
Healthy Participants
Interventions
DRUG

HL-1186

HL-1186 tablet for oral administration.

DRUG

HL-1186 placebo

HL-1186 placebo tablet for oral administration.

Trial Locations (1)

Unknown

RECRUITING

Jiangnan University Affiliated Hospital, Wuxi

All Listed Sponsors
lead

Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.

INDUSTRY